Thirty-Six Hours of Influenza in a Man With COPD: Choosing and Dosing an Antiviral, and Why an Antibiotic Is Not the Answer
[Student Name]
University of Phoenix
NSG/522: Advanced Pharmacology
Week 2 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. No real patient is described.
In January, a composite 67-year-old retired machinist with chronic obstructive pulmonary disease (COPD), type 2 diabetes and stage 3 chronic kidney disease called his nurse practitioner's clinic after 36 hours of fever to 38.8 C, chills, body aches, headache and a worsening dry cough. At a same-day visit his oxygen saturation was 93% on room air, his usual baseline, his lungs had scattered wheezes without focal crackles and a rapid molecular test was positive for influenza A. His estimated creatinine clearance, calculated from his age, weight and serum creatinine, was 44 mL/min. He asked for "a Z-Pak, like last time." What would help him was a drug that stops the virus from spreading between his cells, chosen and dosed for his lungs and his kidneys, not an antibiotic aimed at bacteria he did not have. This paper explains the pharmacologic choice.
Why Treatment Is Indicated
Most healthy adults recover from influenza without antivirals, but this patient is at high risk of complications because of his age, COPD and diabetes. The Infectious Diseases Society of America guideline recommends antiviral treatment as soon as possible for outpatients with confirmed or suspected influenza who are at high risk of complications, regardless of vaccination status or illness duration, and notes that benefit is greatest when treatment starts within 48 hours of symptom onset (Uyeki et al., 2019). At 36 hours, he is within that window.
Mechanisms of the Available Antivirals
Neuraminidase inhibitors, including oral oseltamivir, inhaled zanamivir and intravenous peramivir, block the viral enzyme neuraminidase. Influenza virions bud from infected cells but remain attached to sialic acid on the cell surface until neuraminidase cleaves it. Blocking the enzyme traps new virions on the cell surface and prevents them from spreading to neighboring cells, reducing viral replication and allowing the immune system to clear the infection. Because the drugs act on viral spread rather than on infected cells, they work best early, when replication is at its peak.
Baloxavir marboxil works at a different step. It inhibits the cap-dependent endonuclease of the viral polymerase, which the virus uses to steal the caps of host messenger RNA to make its own, and so it blocks viral RNA transcription. Hayden et al. (2018) found that a single dose of baloxavir shortened symptoms compared with placebo and reduced viral load faster than oseltamivir in otherwise healthy adults and adolescents, although viral variants with reduced susceptibility emerged in some treated patients.
Choosing Among the Options
Zanamivir is inhaled as a dry powder and can cause bronchospasm; it is not recommended for people with underlying airway disease such as COPD or asthma (Uyeki et al., 2019). For this patient, it is the wrong choice regardless of efficacy. Peramivir is given intravenously and is used mainly when oral therapy is not possible. Baloxavir is an option for high-risk outpatients, but it has less evidence in older adults with multiple chronic conditions, and the potential for resistance is a consideration.
Oseltamivir has the largest body of evidence and is the guideline's preferred agent for most high-risk outpatients. Dobson et al. (2015), in an individual patient data meta-analysis of randomized trials in adults, found that oseltamivir shortened the time to symptom alleviation in people with confirmed influenza and reduced lower respiratory tract complications requiring antibiotics, at the cost of more nausea and vomiting.
Pharmacokinetics and Renal Dose Adjustment
Oseltamivir phosphate is an oral prodrug that is well absorbed and converted by hepatic esterases to oseltamivir carboxylate, the active form. The carboxylate is not metabolized further and is eliminated almost entirely by the kidneys through glomerular filtration and tubular secretion. Reduced kidney function therefore raises and prolongs drug levels.
The standard adult treatment dose is 75 mg twice daily for five days. For a creatinine clearance above 30 and up to 60 mL/min, the labeled dose is reduced to 30 mg twice daily for five days (Uyeki et al., 2019). With a creatinine clearance of 44 mL/min, this patient receives 30 mg twice daily. Using the full dose would not be dangerous in the short term, since oseltamivir has a wide margin of safety, but dosing to kidney function is the correct practice and reduces gastrointestinal side effects.
Why Not an Antibiotic
The patient's request for azithromycin reflects a common belief that antibiotics treat respiratory infections. Antibiotics have no activity against influenza virus. They are indicated only when there is evidence of a bacterial complication, such as pneumonia with focal findings, new infiltrate on imaging or clinical worsening after initial improvement. Unnecessary antibiotics cause side effects such as diarrhea and Clostridioides difficile infection, drug interactions and antimicrobial resistance. Azithromycin also prolongs the QT interval. The nurse practitioner explained that the antiviral treats the cause of his illness, that his lungs showed no sign of bacterial pneumonia and what symptoms would change that assessment.
Drug Interactions and Other Medications
Oseltamivir has few clinically important drug interactions because it is not metabolized by the cytochrome P450 system and is only modestly protein bound, which makes it easy to add to a complex medication list such as his, which includes metformin, a long-acting inhaled bronchodilator, an inhaled corticosteroid and lisinopril. Two practical points still matter. Live attenuated influenza vaccine should not be given within two weeks after antiviral treatment, since the antiviral can inactivate the vaccine virus; the inactivated injectable vaccine is unaffected. And metformin should be reviewed if he develops vomiting or dehydration, since his reduced kidney function raises the risk of lactic acidosis during acute illness.
Adverse Effects and Teaching
The most common side effects of oseltamivir are nausea and vomiting, which are reduced by taking the medication with food. Rare neuropsychiatric events, including confusion and abnormal behavior, have been reported, mostly in children and adolescents, and influenza itself can cause similar symptoms. The patient was taught to take each dose with food, to complete the five-day course, to continue his COPD inhalers, to monitor his blood glucose more often because acute illness can raise it and to seek care immediately for worsening shortness of breath, chest pain, confusion, a return of fever after improvement or oxygen saturation below his usual level on his home oximeter.
Protecting the Household
His wife, age 64, lives with him and has not received the current season's influenza vaccine. Antiviral chemoprophylaxis can be considered for household contacts at high risk of complications, and oseltamivir 75 mg once daily for seven days after the last exposure is the usual prophylactic regimen for adults with normal kidney function (Uyeki et al., 2019). She was offered prophylaxis and vaccination, which remains useful even after exposure has begun because it protects against other circulating strains and future exposures.
Conclusion
A high-risk older adult with COPD, diabetes and reduced kidney function presenting within 48 hours of confirmed influenza meets clear criteria for antiviral treatment. Understanding the drugs' mechanisms, evidence and pharmacokinetics leads to oseltamivir rather than inhaled zanamivir, at a dose reduced for his creatinine clearance, with teaching to manage side effects and recognize complications. An antibiotic would treat nothing he has and add risk. The same pharmacologic reasoning extends to protecting his household through prophylaxis and vaccination.
References
Dobson, J., Whitley, R. J., Pocock, S., & Monto, A. S. (2015). Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. The Lancet, 385(9979), 1729-1737. https://doi.org/10.1016/S0140-6736(14)62449-1
Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T., & Watanabe, A. (2018). Baloxavir marboxil for uncomplicated influenza in adults and adolescents. New England Journal of Medicine, 379(10), 913-923. https://doi.org/10.1056/NEJMoa1716197
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Jr., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., Ison, M. G., Johnston, B. L., Knight, S. L., McGeer, A., Riley, L. E., Wolfe, C. R., Alexander, P. E., & Pavia, A. T. (2019). Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clinical Infectious Diseases, 68(6), e1-e47. https://doi.org/10.1093/cid/ciy866
How this NSG 522 Week 2 example is structured
The University of Phoenix library guide for NSG/522 lists Week 2 as Antibiotics, Antivirals, and Infectious Disease. The paper builds the prescribing decision from the patient's risk factors, the drugs' mechanisms and the evidence of benefit, so the choice follows from pharmacology rather than habit. The renal dosing calculation is shown, the rejected options are explained and the section on antibiotics addresses the most common prescribing error in respiratory viral illness. Students search this week as NSG 522 Week 2, NSG522 Wk 2 or NSG/522 Wk 2; all three are the same assignment.
NSG/522 Week 2 questions, answered
What does NSG/522 Week 2 usually ask for?
The library guide for NSG/522 lists Week 2 as antibiotics, antivirals and infectious disease. Many sections ask for a paper or case analysis on selecting an anti-infective for a patient, including mechanism, dosing, adverse effects and stewardship.
Is oseltamivir useful after 48 hours of symptoms?
For healthy outpatients the benefit is greatest when started within 48 hours. For patients at high risk of complications or who are hospitalized, guidelines recommend treatment even when started later, because it may still reduce complications.
Why avoid zanamivir in COPD?
Zanamivir is inhaled as a dry powder and can cause bronchospasm, which can be serious in people with asthma or COPD. Oral or intravenous alternatives are preferred for these patients.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.